Building Cell Therapy Companies With Kenai Therapeutics' Nick Manusos
Streams straight from the publisher. podnod never proxies or re-hosts episode audio.
We love to hear from our listeners. Send us a message.
On this week's episode of the Business of Biotech, Nick Manusos, CEO at Kenai Therapeutics, talks about his experiences building cell therapy spinouts from FujiFilm Cellular Dynamics, learning from big pharma decision-making processes, and dosing the first patient with Kenai's allogeneic neuron replacement cell therapy for Parkinson's disease. Nick also talks about funding an early-stage cell therapy company and forging key manufacturing and therapy administration partnerships.
Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.
Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com
Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/
We love to hear from our listeners. Send us a message.
buzzsprout.comBusiness of Biotech
lifescienceleader.comBusiness of Biotech newsletter
www9.lifescienceleader.comhttps://www.linkedin.com/in/bencomer/
linkedin.com
- 0:00Meet Nick Manuso And His Journey
- 4:35Big Pharma vs Startup Decision Making
- 6:40Why Cell Therapy And How He Learned It
- 9:50Spinning Out Century And Opsis
- 12:20Founding Kenai And Rebrand Strategy
- 15:10Raising A Series A In A Tough Market
- 17:10Inside RNDP-001 And Donor Source
- 19:35Surgery, Dosing, And Immunosuppression Light
- 21:05Trial Timelines And What Success Looks Like
- 23:25Addressable Patients And Site Footprint
- 24:55Manufacturing Scale And Tech Transfer
- 27:00Partner Ecosystem And CIRM Support
- 29:00Funding Paths And Market Outlook
- 30:20Lilly Gateway Labs And Team Hubs
- 31:40Pipeline Beyond Parkinson’s
- 34:00Patient Advisory Board And Design Input
- 36:10Near‑Term Focus And Pivotal Planning
- 37:50Personal Priorities And Closing